Patents by Inventor Christoph Seidel

Christoph Seidel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8569515
    Abstract: The trivalent phosphorous atom of a compound is reacted with a reagent in such a manner that a stable phosphate mimetic or a specifier is formed. Phosphoramidites with a phosphorous atom containing at least one hydroxyl residue which is provided with a protective group are reacted for this purpose with a free hydroxyl group: In the first synthesis cycle the hydroxyl group is linked to a solid support via a cleavable or non-cleavable linker. In further synthesis cycles the hydroxyl group is created by cleavage of the protective group from the growing oligomer. This results in formation of a phosphorous acid triester which is reacted with azides. By selecting suitable monomers for the synthesis which have a defined stereoconformation compounds of Formula 1 are produced in a stereocontrolled manner.
    Type: Grant
    Filed: May 3, 2011
    Date of Patent: October 29, 2013
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Dieter Heindl, Dirk Kessler, Angelika Roesler, Christoph Seidel, Wilma Thuer
  • Patent number: 8057997
    Abstract: The present invention is in the field of nucleic acid binding compounds comprising 7-substituted 7-deaza-8aza-2,6-diamino-purine bases, compounds useful for the preparation of such compounds, various uses thereof and methods for the determination of nucleic acids using said compounds in the field of diagnostics.
    Type: Grant
    Filed: April 30, 2007
    Date of Patent: November 15, 2011
    Assignee: Roche Molecular Systems, Inc.
    Inventors: Frank Seela, Frank Bergmann, Herbert Von Der Eltz, Dieter Heindl, Christoph Seidel, Georg Becher
  • Publication number: 20110212861
    Abstract: The trivalent phosphorous atom of a compound is reacted with a reagent in such a manner that a stable phosphate mimetic or a specifier is formed. Phosphoramidites with a phosphorous atom containing at least one hydroxyl residue which is provided with a protective group are reacted for this purpose with a free hydroxyl group: In the first synthesis cycle the hydroxyl group is linked to a solid support via a cleavable or non-cleavable linker. In further synthesis cycles the hydroxyl group is created by cleavage of the protective group from the growing oligomer. This results in formation of a phosphorous acid triester which is reacted with azides. By selecting suitable monomers for the synthesis which have a defined stereoconformation compounds of Formula 1 are produced in a stereocontrolled manner.
    Type: Application
    Filed: May 3, 2011
    Publication date: September 1, 2011
    Inventors: Dieter Heindl, Dirk Kessler, Angelika Roesler, Christoph Seidel, Wilma Thuer
  • Publication number: 20110021365
    Abstract: The present invention is in the field of nucleic acid binding compounds comprising 7-substituted 7-deaza-8aza-2,6-diamino-purine bases, compounds useful for the preparation of such compounds, various uses thereof and methods for the determination of nucleic acids using said compounds in the field of diagnostics.
    Type: Application
    Filed: April 30, 2007
    Publication date: January 27, 2011
    Inventors: Frank Seela, Frank Bergmann, Herbert Von Der Eltz, Dieter Heindl, Christoph Seidel, Georg Becher
  • Patent number: 7811770
    Abstract: The present invention relates to antibodies specifically binding to native proBNP, a method for specific detection of native proBNP, a method of correlating the level of native proBNP to the diagnosis of heart failure, a kit for detection of native proBNP and to a hybridoma cell line producing an antibody to native proBNP.
    Type: Grant
    Filed: December 22, 2006
    Date of Patent: October 12, 2010
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Anneliese Borgya, Andreas Gallusser, Michael Grol, Klaus Hallermayer, Volker Klemt, Christoph Seidel
  • Patent number: 7807380
    Abstract: The present invention relates to antibodies specifically binding to native proBNP, a method for specific detection of native proBNP, a method of correlating the level of native proBNP to the diagnosis of heart failure, a kit for detection of native proBNP and to a hybridoma cell line producing an antibody to native proBNP.
    Type: Grant
    Filed: December 5, 2006
    Date of Patent: October 5, 2010
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Anneliese Borgya, Andreas Gallusser, Michael Grol, Klaus Hallermayer, Volker Klemt, Christoph Seidel
  • Publication number: 20100136519
    Abstract: The invention concerns a process for the immunological determination of a specific antibody in a fluid sample. The process involves incubating the fluid sample in the presence of a solid phase with two antigens directed against the antibody whose presence is to be determined; the first antigen carries at least one marker group, while the second is either (a) bonded to the solid phase or (b) present in a form in which it can bond with the solid phase, and betrays the presence of the antibody being sought by showing the presence of the marker group in the solid phase and/or in the fluid phase. The proposed process is characterised by the fact that at least one of the two antigens has several epitopic regions which react with the antibody to be determined.
    Type: Application
    Filed: October 27, 2009
    Publication date: June 3, 2010
    Applicant: Roche Diagnostics GmbH
    Inventors: Ursula-Henrike Wienhues, Cornelia Kruse-Müller, Eva Höss, Elke Faatz, Beatus Ofenloch-Hähnle, Christoph Seidel, Michael Wiedmann
  • Patent number: 7629295
    Abstract: The invention concerns a method for the immunological determination of a specific antibody in a sample liquid in which the sample liquid is incubated in the presence of a solid phase with two antigens directed against the antibody to be determined of which the first antigen carries at least one marker group and the second antigen is (a) bound to the solid phase or (b) is present in a form capable of binding to the solid phase and the antibody to be determined is detected by determining the marker group in the solid phase or/and in the liquid phase characterized in that at least one of the two antigens contains several epitope regions which react with the antibody to be determined.
    Type: Grant
    Filed: July 7, 2003
    Date of Patent: December 8, 2009
    Assignee: Roche Diagnostics GmbH
    Inventors: Ursula-Henrike Wienhues, Cornelia Kruse-Müller, Eva Höss, Elke Faatz, Beatus Ofenloch-Hähnle, Christoph Seidel, Michael Wiedmann
  • Patent number: 7560231
    Abstract: The present invention is related to compounds comprising mannitol or glucitol derivatives which may be used to build up oligomeric compounds. The invention is further related to uses of these oligomeric compounds for hybridization and as probes. In addition, methods for the detection of nucleic acids are disclosed wherein the oligomeric compounds are used.
    Type: Grant
    Filed: December 5, 2003
    Date of Patent: July 14, 2009
    Assignee: Roche Molecular Systems, Inc.
    Inventors: Frank Bergmann, Herbert Von Der Eltz, Christoph Seidel, Kurt Weindel
  • Publication number: 20090098528
    Abstract: The present invention concerns a polypeptide which is composed of the amino acids 1207±10 to 1488±10 of a hepatitis C virus and of less than 20 foreign amino acids and the use of this polypeptide as an antigen in an immunological test.
    Type: Application
    Filed: October 11, 2007
    Publication date: April 16, 2009
    Inventors: Christoph Seidel, Ursula-Henrike Wienhues, Urban Schmitt, Manfred Motz, Michael Wiedmann, Barbara Upmeier, Erwin Soutscheck
  • Publication number: 20080187904
    Abstract: The invention concerns a process for the production of metal chelate-labelled peptide antigens, peptides obtainable by this process and their use in an immunological method of detection.
    Type: Application
    Filed: February 6, 2008
    Publication date: August 7, 2008
    Applicant: Roche Diagnostics GmbH
    Inventors: Christoph Seidel, Ursula-Henrike Wienhues, Eva Hoss
  • Patent number: 7390624
    Abstract: The invention concerns a process for the production of metal chelate-labelled peptide antigens, peptides obtainable by this process and their use in an immunological method of detection.
    Type: Grant
    Filed: February 10, 2003
    Date of Patent: June 24, 2008
    Assignee: Roche Diagnostics GmbH
    Inventors: Christoph Seidel, Ursula-Henrike Wienhues, Eva Höss
  • Patent number: 7348423
    Abstract: A process is disclosed for the production of an antifusogenic peptide by producing a fusion peptide of a length of about 14 to 70 amino acids in a prokaryotic host cell, comprising the steps, under such conditions that inclusion bodies of said fusion peptide are formed, of: (a) expressing in said host cell a nucleic acid encoding said fusion peptide consisting of a first peptide which is an antifusogenic peptide of a length of about 10 to 50 amino acids and a second peptide of a length of about 4 to 30 amino acids, said first peptide being N-terminally linked to said second peptide; (b) cultivating said host cell to produce said inclusion bodies; and (c) recovering said antifusogenic peptide from said inclusion bodies, wherein said recovered antifusogenic peptide consists of said fusion peptide or a peptide comprising the antifusogenic peptide of about 10 to 50 amino acids and which is a fragment cleaved from said fusion peptide. Inclusion bodies of the peptides are disclosed.
    Type: Grant
    Filed: October 20, 2004
    Date of Patent: March 25, 2008
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Eva Hoess, Thomas Meier, Gabriele Pestlin, Friedrich Popp, Klaus Reichert, Rainer Schmuck, Bernd Schneidinger, Christoph Seidel, Wilhelm Tischer
  • Patent number: 7264939
    Abstract: The present invention relates to antibodies specifically binding to native proBNP, a method for specific detection of native proBNP, a method of correlating the level of native proBNP to the diagnosis of heart failure, a kit for detection of native proBNP and to a hybridoma cell line producing an antibody to native proBNP.
    Type: Grant
    Filed: November 10, 2005
    Date of Patent: September 4, 2007
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Anneliese Borgya, Andreas Gallusser, Michael Grol, Klaus Hallermayer, Volker Klemt, Christoph Seidel
  • Patent number: 7264938
    Abstract: The present invention relates to antibodies specifically binding to native proBNP, a method for specific detection of native proBNP, a method of correlating the level of native proBNP to the diagnosis of heart failure, a kit for detection of native proBNP and to a hybridoma cell line producing an antibody to native proBNP.
    Type: Grant
    Filed: November 10, 2005
    Date of Patent: September 4, 2007
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Anneliese Borgya, Andreas Gallusser, Michael Grol, Klaus Hallermayer, Volker Klemt, Christoph Seidel
  • Patent number: 7238795
    Abstract: The present invention is in the field of nucleic acid binding compounds comprising 7-substituted 7-deaza-8aza-2,6-diamino-purine bases, compounds useful for the preparation of such compounds, various uses thereof and methods for the determination of nucleic acids using said compounds in the field of diagnostics.
    Type: Grant
    Filed: July 31, 2001
    Date of Patent: July 3, 2007
    Assignee: Roche Molecular Systems, Inc.
    Inventors: Frank Seela, Frank Bergmann, Herbert Von Der Eltz, Dieter Heindl, Christoph Seidel, Georg Becher
  • Publication number: 20070117156
    Abstract: The present invention relates to antibodies specifically binding to native proBNP, a method for specific detection of native proBNP, a method of correlating the level of native proBNP to the diagnosis of heart failure, a kit for detection of native proBNP and to a hybridoma cell line producing an antibody to native proBNP.
    Type: Application
    Filed: December 22, 2006
    Publication date: May 24, 2007
    Inventors: Anneliese Borgya, Andreas Gallusser, Michael Grol, Klaus Hallermayer, Volker Klemt, Christoph Seidel
  • Publication number: 20070099241
    Abstract: The present invention relates to antibodies specifically binding to native proBNP, a method for specific detection of native proBNP, a method of correlating the level of native proBNP to the diagnosis of heart failure, a kit for detection of native proBNP and to a hybridoma cell line producing an antibody to native proBNP.
    Type: Application
    Filed: December 5, 2006
    Publication date: May 3, 2007
    Inventors: Anneliese Borgya, Andreas Gallusser, Michael Grol, Klaus Hallermayer, Volker Klemt, Christoph Seidel
  • Patent number: 7122302
    Abstract: The present invention concerns a polypeptide which is composed of the amino acids 1207±10 to 1488±10 of a hepatitis C virus and of less than 20 foreign amino acids and the use of this polypeptide as an antigen in an immunological test.
    Type: Grant
    Filed: June 29, 2001
    Date of Patent: October 17, 2006
    Assignee: Roche Diagnostic GmbH
    Inventors: Christoph Seidel, Ursula-Henrike Wienhues, Urban Schmitt, Manfred Motz, Michael Wiedmann, Barbara Upmeier, Erwin Soutschek
  • Publication number: 20060110775
    Abstract: The present invention relates to antibodies specifically binding to native proBNP, a method for specific detection of native proBNP, a method of correlating the level of native proBNP to the diagnosis of heart failure, a kit for detection of native proBNP and to a hybridoma cell line producing an antibody to native proBNP.
    Type: Application
    Filed: November 10, 2005
    Publication date: May 25, 2006
    Inventors: Anneliese Borgya, Andreas Gallusser, Michael Grol, Klaus Hallermayer, Volker Klemt, Christoph Seidel